ICB agents, in the form of antibodies, binding to these ligands/receptors (anti-CTLA-4 and anti-PD-1/anti-PD-L1) can overcome inhibitory signaling and reactivate T-cell engagement toward the tumor (Fig. 4). The gene discussed is CD274; the disease is neoplasm.